- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940712
Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements.
This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Rebekah L Trotti, PhD
- Numéro de téléphone: 617-754-1262
- E-mail: rtrotti@bidmc.harvard.edu
Sauvegarde des contacts de l'étude
- Nom: Brendan Stiltner, BS
- E-mail: bstiltne@bidmc.harvard.edu
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Beth Israel Deaconess Medical Center
-
Contact:
- Rebekah L Trotti, PhD
- Numéro de téléphone: 617-754-1262
- E-mail: rtrotti@bidmc.harvard.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Proficient in English
- IQ >= 80
Exclusion Criteria:
- Major neurological conditions
- Implanted devices in the body or metal in the head
- Changes to relevant medications within 1 month of enrollment
- Pregnancy or breastfeeding
- Moderate to severe DSM V substance use disorder
- Clinical instability including recent or severe suicidal ideation or actions
- Positive urine drug screen for illicit substances
- Skin allergy to lidocaine or electrolyte gel
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: NIBS+
Combined transcranial direct current stimulation and cognitive remediation therapy (both active) |
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Autres noms:
Active cognitive remediation therapy. Cognitive exercises are delivered with NeuropsychOnline and administered by a trained coach.
Autres noms:
|
|
Comparateur actif: NIBS-
Transcranial direct current stimulation and sham cognitive remediation therapy (active tDCS and sham CRT) |
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Autres noms:
An active comparator for cognitive remediation therapy, delivered with quizzes collected from Sporcle.com.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Functional connectivity with the prefrontal cortex
Délai: Pre-intervention to post-intervention at 2-weeks
|
Participants will be directed to keep their eyes open and loosely fixed on a plus sign on the screen in front of them for 5 minutes while EEG is recorded. Resting data will be cleaned, processed, and transformed to 4 frequency band values: delta/theta, alpha, beta, and gamma. Frequency data will be converted to connectivity values using weighted phase lag index (wPLI). Average connectivity of all sensors with the prefrontal sensor F3 will be calculated and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Brief Assessment of Cognition Digit Sequencing (Working Memory)
Délai: Pre-intervention to post-intervention at 2-weeks
|
Participants will arrange random number strings in ascending order during the Brief Assessment of Cognition. This score, which indexes working memory is called Digit Sequencing and will be z-scored according to published norms and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Brief Assessment of Cognition subdomains
Délai: Pre-intervention to post-intervention at 2-weeks
|
Participants will complete the Brief Assessment of Cognition, which includes tasks indexing psychomotor and visual processing speed, lexical access, attention and processing speed, and executive functioning, called Token Motor, Verbal Fluency, Symbol Coding, and Tower of London, respectively. These subdomain scores will be normed and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026P000528
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Only IPD used in the results publication will be shared.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .